Mark A. Wan's most recent trade in Talphera Inc. was a trade of 13,044 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 24, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Talphera Inc. | Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
Talphera Inc. | Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,592 (0%) | 0% | 0 | Common Stock | |
Acelrx Pharmaceuticals Inc | Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 3,487 | 3,487 | - | - | Stock Option (Right to Buy) | |
Acelrx Pharmaceuticals Inc | Wan Mark A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 581 | 2,418 (0%) | 0% | 0 | Common Stock | |
Acelrx Pharmaceuticals Inc | Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
Acelrx Pharmaceuticals Inc | Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 10,000 | 21,250 (0%) | 0% | 0 | Common Stock | |
Acelrx Pharmaceuticals Inc | Mark A. Wan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
Acelrx Pharmaceuticals Inc | Mark A. Wan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 7,500 | 11,250 (0%) | 0% | 0 | Common Stock |